A significant body of evidence suggests that inhibition of GCPII by inhibitors provides substantial neuroprotection in various neuropathological disorders, including cerebral ischemia, spinal cord and TBI, inflammatory and neuropathic pain, motoneuron disease, peripheral neuropathy, epilepsy, and drug abuse.34, 35, 37, 38. Here, FOLH1 is linked to epilepsy.